• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Soligenix, Inc. - Common Stock (NQ:SNGX)

    2.070 -0.100 (-4.61%)
    Streaming Delayed Price Updated: 3:40 PM EDT, Apr 28, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 40,933
    Open 2.240
    Bid (Size) 2.050 (1)
    Ask (Size) 2.140 (1)
    Prev. Close 2.170
    Today's Range 2.015 - 2.240
    52wk Range 1.680 - 14.83
    Shares Outstanding 3,155,603
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in Benzinga Video Highlighting 75% HyBryte™ Response Rate in FDA-Backed Skin Cancer Trial
    Via Investor Brand Network
    Soligenix's HyBryte(TM) Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Exposures Product Safety

    Performance

    YTD
    -29.6%
    -29.6%
    1 Month
    -6.3%
    -6.3%
    3 Month
    -16.9%
    -16.9%
    6 Month
    -47.7%
    -47.7%
    1 Year
    -68.8%
    -68.8%

    More News

    Read More
    Soligenix's HyBryte(TM) Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding
    Via TheNewswire.com
    Exposures Product Safety
    Soligenix Inc. (NASDAQ: SNGX) Advances CiVax Amid Ongoing COVID-19 Threat
    Via Investor Brand Network
    Topics Death
    Exposures COVID-19 Death
    Study Finds Link Between Childhood Maltreatment and Elevated Risk of Psoriasis, Rheumatoid Arthritis
    Via Investor Brand Network
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Study Shows the Gut is Key in Protecting the Brain After Stroke
    Via Investor Brand Network
    Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Recent Zacks Small-Cap Research Report, Earns a $35 Valuation
    Via Investor Brand Network
    Soligenix Inc. (NASDAQ: SNGX) Advances Phase 3 Replication Study for Early-Stage Cutaneous T-Cell Lymphoma Treatment
    Via Investor Brand Network
    BioMedNewsBreaks — Zacks Maintains $35.00 Price Per Share Valuation for Soligenix Inc. (NASDAQ: SNGX) Amid Promising Vaccine and CTCL Therapy Progress
    Via Investor Brand Network
    Exposures COVID-19
    InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Taps IBN to Lead Corporate Communications Strategy
    Via Investor Brand Network
    Exposures COVID-19
    InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Announces Key Milestones and 2024 Financial Results
    Via Investor Brand Network
    Exposures COVID-19
    Study Shows Bioengineered Materials Can Treat Oral Mucositis
    Via Investor Brand Network
    BioMedNewsBreaks — Why Soligenix Inc. (NASDAQ: SNGX) Is ‘One to Watch’
    Via Investor Brand Network
    Exposures COVID-19
    Soligenix Inc. (NASDAQ: SNGX) Is ‘One to Watch’
    Via Investor Brand Network
    Soligenix Aims To Push The Boundaries In Treating Rare Diseases
    Via NewMediaWire
    Soligenix Aims To Push The Boundaries In Treating Rare Diseases
    Via TheNewswire.com
    Improving Patient Quality Of Life: Soligenix Progresses Treatment For Painful Ulcers Associated With Rare Behcet's Disease
    Via NewMediaWire
    Improving Patient Quality Of Life: Soligenix Progresses Treatment For Painful Ulcers Associated With Rare Behcet's Disease
    Via TheNewswire.com
    Soligenix's Leadership Aims To Drive Growth In Rare Disease Markets In 2025 And 2026
    Via NewMediaWire
    Exposures COVID-19
    Soligenix's Leadership Aims To Drive Growth In Rare Disease Markets In 2025 And 2026
    Via TheNewswire.com
    Exposures COVID-19
    Soligenix Targets Psoriasis With New Therapy
    Via News Direct
    EXCLUSIVE: Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year
    Via Benzinga
    Soligenix Reports It Is On Cusp Of Treating Rare Cancer CTCL
    Via News Direct
    EXCLUSIVE: Soligenix Starts Confirmatory Late-Stage Trial For HyBryte For Type Of Blood Cancer
    Via Benzinga

    Frequently Asked Questions

    Is Soligenix, Inc. - Common Stock publicly traded?
    Yes, Soligenix, Inc. - Common Stock is publicly traded.
    What exchange does Soligenix, Inc. - Common Stock trade on?
    Soligenix, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Soligenix, Inc. - Common Stock?
    The ticker symbol for Soligenix, Inc. - Common Stock is SNGX on the Nasdaq Stock Market
    What is the current price of Soligenix, Inc. - Common Stock?
    The current price of Soligenix, Inc. - Common Stock is 2.070
    When was Soligenix, Inc. - Common Stock last traded?
    The last trade of Soligenix, Inc. - Common Stock was at 04/28/25 03:40 PM ET
    What is the market capitalization of Soligenix, Inc. - Common Stock?
    The market capitalization of Soligenix, Inc. - Common Stock is 6.53M
    How many shares of Soligenix, Inc. - Common Stock are outstanding?
    Soligenix, Inc. - Common Stock has 7M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.